SecBot SecBot
PRESS-RELEASE ·Filed Aug 26, 2026

MESO

Mesoblast Limited
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The massive revenue inflection from RYONCIL commercialization and the completion of the Phase 3 CLBP trial enrollment are significant catalysts. Traders should watch for the mid-CY2027 rexlemestrocel-L readout and any updates on the adult SR-aGvHD label expansion trial. The stock has historically shown high volatility around catalysts, so position sizing should account for binary risk.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

MESO drug pipeline →

rexlemestrocel-L

▲ Bullish Named in this press release
Impact
Phase
Phase 3 / Filed BLA
Time to market
LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
Next catalyst
None dated

What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$18.18
T+0 close · Aug 26, 2026 · via day close
Latest settled
−14.85%
T+20 · $15.48 · next T+60 in 3d
Vs SPY
−14.34%
α at T+20
Latest observation
−22.43%
T+55 · FF3 residual α
  1. T+0 · Aug 27 $18.18entry
  2. T+1 · 3mo ago −4.07%α −3.84% · $17.44
  3. T+5 · 3mo ago −5.72%α −5.99% · $17.14
  4. T+20 · 8w ago −14.85%α −14.34% · $15.48
  5. T+56 · todayOpen
  6. T+60 · in 3d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2M in FY2025, driven by the first full year of RYONCIL commercial launch. Net loss narrowed 44% to $57.5M, and the company completed enrollment in a pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. The massive revenue growth and pipeline progress are bullish, but the company remains unprofitable and the stock has a history of volatile post-earnings moves.

Key Financial Metrics

EPS
−$0.04
est −$0.03
Revenue
$120.3M
est $47.1M · +155.4% · +599.0% YoY
Rating
strong beat
Free Cash Flow
-$44.6M
Gross Margin
86.14%

Key Facts

  • FY2026 total revenue of $120.3M vs $17.2M in FY2025, a 599% increase.
  • RYONCIL net revenue of $115.2M in its first full commercial year.
  • Gross profit of $103.6M vs $5.1M in FY2025.
  • Net loss reduced 44% to $57.5M from $102.1M.
  • Phase 3 trial of rexlemestrocel-L for chronic low back pain completed enrollment with 350 patients; top-line results expected mid-CY2027.
  • Cash balance of $103M at period end; entered a $125M non-dilutive credit facility.
  • EPS of -$0.0444 per share (basic and diluted) vs -$0.0846 in FY2025.

Financial Impact

Revenue increased by $103.1M YoY; net loss improved by $44.6M YoY.

revenuenet lossgross profitcash

Risk Factors

  • RYONCIL revenue growth may decelerate as initial launch pent-up demand normalizes.
  • Phase 3 CLBP trial results are binary and not expected until mid-CY2027.
  • Company remains unprofitable with accumulated losses of $1.07B.
  • Dependence on successful label expansion into adult SR-aGvHD for sustained growth.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3351749

Track record

25 reports on MESO

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
  2. Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
  4. Oct 29, 202618d ago 6-K Bullish 6/10 No price data
  5. Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
  6. Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
  7. Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
  8. Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
  9. Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
  10. Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 26, 2026